-
Ra Pharmaceuticals Inc (NASDAQ: RARX) shares
dipped 22 percent to $17.30 after the company issued updates on Phase 2 trial of RA101495.
-
Xenon Pharmaceuticals Inc (NASDAQ: XENE) shares
dropped 20.6 percent to $3.02 after the company reported results from Phase II study of TV-45070 in patients with PHN. The
study did not meet primary and secondary endpoints.
-
Rewalk Robotics Ltd (NASDAQ: RWLK) shares dropped
18.3 percent to $2.45 after surging 25.00 percent on Monday.
-
Alder Biopharmaceuticals Inc (NASDAQ: ALDR)
shares declined 17.7 percent to $15.40 despite PROMISE 1 Phase 3 trial which met primary and secondary endpoints. Several
notable parts of data set were concerning, namely statistical significance for 100mg dose, and against placebo.
-
Camtek LTD. (NASDAQ: CAMT) shares dipped 12.3
percent to $5.18 after rising 2.25 percent on Monday.
-
Finjan Holdings, Inc. (NASDAQ: FNJN) dropped 12.2
percent to $3.18. Finjan priced 3.6 million shares at $3.15 per share.
-
Matinas BioPharma Holdings Inc (NYSE: MTNB) shares
declined 11 percent to $1.78.
-
Presbia PLC (NASDAQ: LENS) shares fell 10.9
percent to $2.41.
-
Digiliti Money Group Inc (NASDAQ: DGLT) shares
declined 10.1 percent to $2.97.
-
Shiloh Industries, Inc. (NASDAQ: SHLO) shares
slipped 9.7 percent to $12.77.
-
IMPINJ Inc (NASDAQ: PI) shares dropped 9.5 percent
to $53.76. Pacific Crest downgraded Impinj from Overweight to Sector Weight.
-
Avis Budget Group Inc. (NASDAQ: CAR) shares fell
8.2 percent to $25.39. Avis announced Monday it has formed a partnership with Alphabet Inc (NASDAQ: GOOGL)’s autonomous car business, Waymo.
-
WhiteHorse Finance Inc (NASDAQ: WHF) slipped 6.6
percent to $13.43. WhiteHorse Finance reported an offering of 2.5 million shares of common stock.
-
ARMOUR Residential REIT, Inc. (NYSE: ARR) shares
declined 5 percent to $26.11. ARMOUR Residential REIT reported a 4.5 million share common stock offering.
-
Neos Therapeutics Inc (NASDAQ: NEOS) shares
declined 4.8 percent to $7.00. Neos Therapeutics reported a $30 million offering of common stock.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.